{
    "name": "calcium gluconate",
    "comment": "Rx, OTC",
    "other_names": [
        "Gluconate",
        "Ca"
    ],
    "classes": [
        "Antidotes",
        "Other",
        "Calcium Salts"
    ],
    "source": "https://reference.medscape.com/drug/calcium-gluconate-344434",
    "pregnancy": {
        "common": [
            "Pregnancy category: C",
            "Lactation: Calcium enters human milk; use with caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Calcium enters human milk; use with caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "IM/SC administration",
                "Ventricular fibrillation during CPR",
                "Hypercalcemia",
                "Digoxin poisonings",
                "Sarcoidosis"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hepatic or renal impairment, cardiovascular disease, acidosis, history of renal calculi",
                "Cardiac arrest may occur",
                "Calcium gluconate injection contains aluminum, up to 100 mcg per liter",
                "Constipation, bloating, and gas may occur with oral administration",
                "Use caution in patients with severe hyperphosphatemia",
                "Adult and Pediatric Advanced Life Support programs no longer recommend routine calcium for CPR",
                "Rapid IV infusion associated with hypotension, bradycardia, syncope, cardiac arrest, cardiac arrhythmias, sense of oppression or heat waves, tingling sensation, vasodilation"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ceftriaxone",
            "description": {
                "common": "ceftriaxone, calcium gluconate. Other (see comment). Contraindicated. \nComment: Do not use ANY calcium containing solutions (including Ringer or Harmann) in combination with IV ceftriaxone; risk of potentially fatal particulate precipitation in lungs, kidneys. Separate by at least 48 hrs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baloxavir marboxil",
            "description": {
                "common": "calcium gluconate will decrease the level or effect of baloxavir marboxil by  cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "calcium gluconate, demeclocycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxycycline",
            "description": {
                "common": "calcium gluconate, doxycycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eltrombopag",
            "description": {
                "common": "calcium gluconate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "minocycline",
            "description": {
                "common": "calcium gluconate, minocycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "calcium gluconate, oxytetracycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetracycline",
            "description": {
                "common": "calcium gluconate, tetracycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "calcium gluconate decreases effects of acebutolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alendronate",
            "description": {
                "common": "calcium gluconate decreases levels of alendronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amlodipine",
            "description": {
                "common": "calcium gluconate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "calcium gluconate decreases effects of atenolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "calcium gluconate decreases effects of betaxolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "calcium gluconate decreases effects of bisoprolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "calcium gluconate decreases effects of carvedilol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "calcium gluconate decreases effects of celiprolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "calcium gluconate decreases effects of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Ciprofloxacin should be administered 2 hr before or 6 hr after calcium salts."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clevidipine",
            "description": {
                "common": "calcium gluconate decreases effects of clevidipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferiprone",
            "description": {
                "common": "calcium gluconate decreases levels of deferiprone by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Deferiprone may bind polyvalent cations (eg, iron, aluminum, and zinc), separate administration by at least 4 hr between deferiprone and other medications (eg, antacids), or supplements containing these polyvalent cations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "delafloxacin",
            "description": {
                "common": "calcium gluconate will decrease the level or effect of delafloxacin by  cation binding in GI tract. Modify Therapy/Monitor Closely. Oral delafloxacin form chelates with alkaline earth and transition metal cations. Administer oral delafloxacin at least 2 hr before or 6 hr after these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "calcium gluconate increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "calcium gluconate decreases effects of diltiazem by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "calcium gluconate decreases effects of esmolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estramustine",
            "description": {
                "common": "calcium gluconate decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Patients should take estramustine with water at least 1h before or 2h after meals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etidronate",
            "description": {
                "common": "calcium gluconate decreases levels of etidronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "calcium gluconate decreases effects of felodipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fleroxacin",
            "description": {
                "common": "calcium gluconate, fleroxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "calcium gluconate, gemifloxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibandronate",
            "description": {
                "common": "calcium gluconate decreases levels of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "calcium gluconate decreases effects of isradipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "calcium gluconate decreases effects of labetalol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "calcium gluconate, levofloxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "calcium gluconate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "calcium gluconate decreases effects of metoprolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "calcium gluconate, moxifloxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "calcium gluconate decreases effects of nadolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "calcium gluconate decreases effects of nebivolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "calcium gluconate decreases effects of nicardipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "calcium gluconate decreases effects of nifedipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "calcium gluconate decreases effects of nisoldipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "calcium gluconate, ofloxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omadacycline",
            "description": {
                "common": "calcium gluconate will decrease the level or effect of omadacycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pamidronate",
            "description": {
                "common": "calcium gluconate decreases levels of pamidronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "calcium gluconate decreases effects of penbutolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "calcium gluconate decreases effects of pindolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium phosphates, IV",
            "description": {
                "common": "calcium gluconate decreases effects of potassium phosphates, IV by cation binding in GI tract. Modify Therapy/Monitor Closely. Calcium decreases serum phosphate concentration by binding dietary phosphate. Use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "calcium gluconate decreases effects of propranolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rilpivirine",
            "description": {
                "common": "calcium gluconate decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Coadministration of antacids with rilpivirine may cause significant decreases in rilpivirine plasma concentrations because of increased gastric pH. If antacids must be administered, they should given at least 2 hr before or at least 4 hr after rilpivirine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risedronate",
            "description": {
                "common": "calcium gluconate decreases levels of risedronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "calcium gluconate will decrease the level or effect of sarecycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium phosphates, IV",
            "description": {
                "common": "calcium gluconate decreases effects of sodium phosphates, IV by cation binding in GI tract. Modify Therapy/Monitor Closely. Calcium decreases serum phosphate concentration by binding dietary phosphate. Use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of calcium gluconate by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of calcium gluconate by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "calcium gluconate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "squill",
            "description": {
                "common": "calcium gluconate increases toxicity of squill by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "strontium ranelate",
            "description": {
                "common": "calcium gluconate decreases levels of strontium ranelate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Applies to oral form of calcium. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiludronate",
            "description": {
                "common": "calcium gluconate decreases levels of tiludronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "calcium gluconate decreases effects of timolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "calcium gluconate decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vitamin D",
            "description": {
                "common": "vitamin D, calcium gluconate. Other (see comment). Use Caution/Monitor. \nComment: The concurrent use of vitamin D with calcium salts is generally beneficial; in some patients this combination may result in hypercalcemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoledronic acid",
            "description": {
                "common": "calcium gluconate decreases levels of zoledronic acid by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin decreases levels of calcium gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amiloride",
            "description": {
                "common": "amiloride decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "bendroflumethiazide increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bumetanide",
            "description": {
                "common": "bumetanide decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "caffeine",
            "description": {
                "common": "caffeine decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcitriol topical",
            "description": {
                "common": "calcitriol topical increases levels of calcium gluconate by pharmacodynamic synergism. Minor/Significance Unknown. Topical calcitriol may lead to hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbonyl iron",
            "description": {
                "common": "calcium gluconate decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "chlorthalidone increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "cyclopenthiazide increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "drospirenone",
            "description": {
                "common": "drospirenone decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "ethacrynic acid decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferric maltol",
            "description": {
                "common": "ferric maltol increases levels of calcium gluconate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferrous fumarate",
            "description": {
                "common": "calcium gluconate decreases levels of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferrous gluconate",
            "description": {
                "common": "ferrous gluconate increases levels of calcium gluconate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferrous sulfate",
            "description": {
                "common": "ferrous sulfate increases levels of calcium gluconate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "furosemide",
            "description": {
                "common": "furosemide decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gentamicin",
            "description": {
                "common": "gentamicin decreases levels of calcium gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "indapamide increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iron dextran complex",
            "description": {
                "common": "calcium gluconate decreases levels of iron dextran complex by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iron sucrose",
            "description": {
                "common": "calcium gluconate decreases levels of iron sucrose by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid decreases levels of calcium gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isotretinoin",
            "description": {
                "common": "isotretinoin increases levels of calcium gluconate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lily of the valley",
            "description": {
                "common": "calcium gluconate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "manganese",
            "description": {
                "common": "calcium gluconate, manganese.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "methyclothiazide increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "metolazone increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "neomycin PO decreases levels of calcium gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paromomycin",
            "description": {
                "common": "paromomycin decreases levels of calcium gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "polysaccharide iron",
            "description": {
                "common": "calcium gluconate decreases levels of polysaccharide iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rose hips",
            "description": {
                "common": "calcium gluconate decreases levels of rose hips by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "shark cartilage",
            "description": {
                "common": "calcium gluconate, shark cartilage. pharmacodynamic synergism. Minor/Significance Unknown. May lead to hypercalcemia (theoretical)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sodium polystyrene sulfonate",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "spironolactone",
            "description": {
                "common": "spironolactone decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "streptomycin",
            "description": {
                "common": "streptomycin decreases levels of calcium gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "teriparatide",
            "description": {
                "common": "teriparatide increases levels of calcium gluconate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tobramycin",
            "description": {
                "common": "tobramycin decreases levels of calcium gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "torsemide",
            "description": {
                "common": "torsemide decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamterene",
            "description": {
                "common": "triamterene decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Hypomagnesemia",
            "percent": null
        },
        {
            "name": "Hypophosphatemia",
            "percent": null
        },
        {
            "name": "Extravasation necrosis",
            "percent": null
        }
    ]
}